Kieren Mather, MD, is vice president of medical incretin and diabetes breakthroughs in the early clinical research division at Eli Lilly, where he leads efforts to develop next-generation treatments for diabetes and metabolic disorders
Download here and learn how a QbD approach helps control release, gastric retention, and product quality: #CrystalPharmatech #ModifiedRelease #Gastroretentive #BilayerTablet #QbD #FormulationDevelopment #DrugDevelopment #CMC #OralDosageForms #Bioavailability To view or add a comment, sign in MiniMed Announces FDA Clearance of MiniMed Flex, the Companys Smallest Insulin Pump Featuring Its First Smartphone-Controlled Design MiniMed Flex is about half the size of the previous generation MiniMed 780G system, and features the SmartGuard adaptive algorithm to automatically adjust and autocorrect insulin delivery in real-time NORTHRIDGE, Calif., March 18, 2026 /PRNewswire/ [...] #LosAngeles #OrangeCountyCA #Biotech #Lifescience #News To view or add a comment, sign in Agarose Explore how agarose turns your raw drug into a precise, deliverable medicine with its gelforming properties
Exenatide twice daily: a review of its use in the management of patients with type 2 diabetes mellitus
Eligible participants were 18 years or older and had type 2 diabetes treated with a combination of metformin, sulfonylurea, or sodium-glucose co-transporter-2 inhibitor
